Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Sci ; 102(2): 772-84, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23192864

ABSTRACT

The ATP-binding cassette subfamily G member 2 (ABCG2) transporter is a member of the ATP-binding cassette (ABC) family of efflux carriers that mediates cellular extrusion of various drugs and toxins. In the mammary gland, ABCG2 is expressed at the apical membrane of alveolar epithelial cells and is induced during lactation. It is well established that ABCG2 plays the main role in active secretion of xenobiotics into milk of humans and mice. In contrast, no detailed information is as yet available about functional activity and substrate spectrum of ABCG2 in dairy animals. Therefore, we cloned full-length ABCG2 from bovine, ovine and caprine lactating mammary gland tissues using rapid amplification of complementary DNA (cDNA) ends polymerase chain reaction. The generated full-length ABCG2 cDNA constructs were stably transduced in MDCKII cells. Functional ABCG2 efflux activity was demonstrated with the Hoechst H33342 accumulation assay using the specific ABCG2 inhibitor Ko143. The established ruminant MDCKII-ABCG2 cell culture models in conjunction with the H33342 transport assay showed interaction of various drugs such as cefalexin and albendazole with bABCG2, oABCG2 or cABCG2. Moreover, the flavonoids equol and quercetin exhibited interaction with all ruminant ABCG2 clones. Altogether, our generated cell culture models allowed rapid and high-throughput screening of potential ruminant ABCG2 substrates and thus increase the understanding of carrier-associated secretion of xenobiotics into milk.


Subject(s)
ATP-Binding Cassette Transporters/physiology , Dairy Products , Lactation/metabolism , Madin Darby Canine Kidney Cells/metabolism , Neoplasm Proteins/physiology , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/metabolism , Animals , Animals, Domestic , Cattle , Female , Flavonoids/metabolism , Goats , Neoplasm Proteins/metabolism , Protein Binding/physiology , Sheep
2.
Pflugers Arch ; 454(4): 587-94, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17333245

ABSTRACT

Cholestatic liver disease and increased serum bile acid concentrations are known to trigger various adaptive responses including the induction of hepatic, intestinal and renal bile acid transport proteins, but renal P-glycoprotein (Pgp, multidrug resistance protein 1, MDR1) remained uninvestigated in this context. We show that treatment of Madin Darby canine kidney (MDCK) cells with pathophysiologically relevant concentrations of chenodeoxycholic acid (CDCA; 100 microM) for 12 h induces MDR1 transcript levels in vitro more than twofold. CDCA and deoxycholic acid pre-treatment for 24-96 h (100 microM) also increased Pgp activity measured as rhodamine efflux, while cholic acid and taurocholic acid were not effective in concentrations up to 600 microM. CDCA pre-treatment (100 microM, 72 h) also resulted in a doubling of rhodamine123 secretion across an epithelium-like monolayer grown on Transwell filters and decreased the sensitivity towards the kidney toxic drugs cyclosporine A and paclitaxel. These findings predict physiologically as well as pharmacologically relevant consequences of liver disease for Pgp substrate transport and toxicity in the kidneys.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Bile Acids and Salts/physiology , Epithelial Cells/metabolism , Kidney/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Animals , Cell Line , Chenodeoxycholic Acid/pharmacology , Cholagogues and Choleretics/pharmacology , Cholic Acid/pharmacology , Cyclosporine/pharmacology , Deoxycholic Acid/pharmacology , Dogs , Enzyme Inhibitors/pharmacology , Epithelial Cells/cytology , Epithelial Cells/drug effects , Gastrointestinal Agents/pharmacology , Gene Expression Regulation/drug effects , Kidney/cytology , Kidney/drug effects , Paclitaxel/pharmacology , Rhodamine 123/metabolism , Taurocholic Acid/pharmacology
3.
Cell Tissue Res ; 320(3): 517-24, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15846510

ABSTRACT

The reduced-folate carrier (Rfc-1), previously also called methotrexate carrier-1 (MTX-1), was recently identified as accounting for approximately 30% of the methotrexate (Mtx) uptake into rat kidney slices. The localization of the carrier and its contribution to secretory or reabsorptive flux of the drug was therefore evaluated in polarized epithelial layers of Madin Darby canine kidney (MDCK) cells. Confocal laser scanning microscopy revealed that the HA-epitope-tagged protein was sorted to the basolateral side. In flux assays, the basolateral-to-apical transport of fluoresceinated methotrexate (FMTX) was two-fold higher than in the apical-to-basolateral direction across rat Rfc-1 transfected, but not mock-transfected, monolayers. The same observation was made for unlabeled Mtx. This secretory transport of FMTX was inhibited by an excess of 1 mM Mtx and was saturable and temperature-dependent. No differences in directional flux were observed for the pure fluorescein label. Removal of sodium resulted in a marked decrease of directional FMTX flux. The pH profile of the active transport component showed a trough around 6.5 and a maximum at acidic pH, as reported for uptake into Rfc-1-expressing cells. Thus, rat Rfc-1 is sorted to the basolateral side in polarized MDCK epithelial cells and mediates the secretion of Mtx, probably in co-operation with efflux proteins, such as multidrug resistance associated proteins, which are also expressed in these cells.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Antirheumatic Agents/pharmacokinetics , Membrane Transport Proteins/metabolism , Methotrexate/analogs & derivatives , Methotrexate/pharmacokinetics , Animals , Biological Transport , Cell Line , Cell Polarity , Dogs , Epithelial Cells/metabolism , Hydrogen-Ion Concentration , Kidney/cytology , Microscopy, Confocal , Minor Histocompatibility Antigens , Rats , Reduced Folate Carrier Protein
4.
Am J Physiol Renal Physiol ; 286(3): F564-71, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14612385

ABSTRACT

Previous Northern blot studies suggested strong expression of a homolog to the sodium-dependent hepatocellular methotrexate transporter in the kidneys. Here, we report on the cloning of the cDNA for the renal methotrexate carrier isoform-1 (RK-MTX-1) and its functional characterization. Sequencing revealed 97% homology to the rat liver methotrexate carrier with an identical open reading frame. Differences were located in the 5'-untranslated region and resulted in the absence of putative regulatory elements (Barbie box, Ah/ARNT receptor) identified in the cDNA for the hepatocellular carrier. For functional characterization, MTX-1 cDNA was stably expressed in Madin-Darby canine kidney (MDCK) cells. A sodium-dependent transport of methotrexate with a K(m) of 41 microM and a V(max) of 337 pmol.mg protein(-1).min(-1) was observed. This uptake was blocked by the reduced folates dihydro- and tetrahydrofolate as well as by methotrexate itself. Folate was inhibiting only weakly, whereas 5-methyltetrahydrofolate was a strong inhibitor. Further inhibitors of the methotrexate transport included the bile acids cholate and taurocholate and xenobiotics like bumetanide and BSP. PAH, ouabain, bumetanide, cholate, taurocholate, and acetyl salicylic acid were tested as potential substrates. However, none of these substances was transported by MTX-1. Furthermore, expression of RK-MTX-1 in MDCK cells enhanced methotrexate toxicity in these cells fivefold. Analysis of a fusion protein of RK-MTX-1 and the influenza virus hemagglutinin epitope by immunoblotting revealed a major band at 72 kDa within the cell membrane but not in the soluble fraction of transfected MDCK. Indirect immunofluorescence staining revealed an exclusive localization of the carrier in the plasma membrane, and by confocal laser-scanning microscopy we were able to demonstrate that the protein is expressed in the serosal region of MDCK tubules grown in a morphogenic collagen gel model.


Subject(s)
Carrier Proteins/genetics , Carrier Proteins/metabolism , Kidney/metabolism , Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Sodium/physiology , Animals , Base Sequence , Biological Transport , Carrier Proteins/analysis , Cell Line , Cloning, Molecular , Dogs , Gene Expression , Kidney/drug effects , Membrane Transport Proteins/analysis , Methotrexate/metabolism , Methotrexate/toxicity , Minor Histocompatibility Antigens , Molecular Sequence Data , Rats , Reduced Folate Carrier Protein , Sequence Alignment
SELECTION OF CITATIONS
SEARCH DETAIL
...